Venture Partners

		Floyd D. Loop, M.D. became a Radius Venture Partner in 2007 after having served on Radius' Advisory Board since 2005. Dr. Loop has been affiliated with The Cleveland Clinic Foundation since 1970, where he most recently served as the Chairman and Chief Executive Officer of the Board of Governors from 1989 to 2004. Dr. Loop was previously Chairman of the Department of Thoracic and Cardiovascular Surgery from 1975 to 1999. Dr. Loop is also the former President of the American Association for Thoracic Surgery and has served in numerous leadership roles in the areas of science and education. He currently serves on the board of directors for Athersys, Inc., a Radius portfolio company, Tenet Healthcare Corporation, and Intuitive Surgical, Inc., and several private corporate boards. He has written extensively, with over 350 publications to date, and has served on numerous healthcare editorial boards. Dr. Loop received his B.S. in Science from Purdue University and his M.D. from George Washington University.
		James M. Mead became a Radius Venture Partner in 2007 after having served on Radius' Advisory Board since 2004. Mr. Mead is the Vice Chairman of the Board of Capital BlueCross (Harrisburg, PA), after having served twenty years as its President and CEO from 1984 to 2004. From 1988 to 2004, he also served on the board of directors of the BlueCross BlueShield Association, sitting on many national committees and chairing its Plan Performance and Financial Standards Committee. He is also the former Chairman of the Board of the Federal Reserve Bank of Philadelphia. Mr. Mead is currently a member of the board of directors of the Hershey Trust Company, the Milton Hershey School, the Milton S. Hershey Foundation, the Greater Harrisburg Foundation, Vitality Group, LLC, and Lebanon Valley College. Mr. Mead holds B.S. and M.A. degrees in economics from Penn State University and was appointed an Alumni Fellow of the University in 1986.
		Dilip J. Mehta, M.D., Ph.D. became a Radius Venture Partner in 2004. Dr. Mehta is the former Senior Vice President of U.S. Clinical Research at Pfizer, Inc., where he was responsible for Phase I, II and III clinical research, including the design and implementation of clinical protocols, statistical analysis, data processing, and submissions of New Drug Applications ("NDA") for Pfizer's pharmaceutical pipeline. During Dr. Mehta's tenure at Pfizer, he supervised NDA submissions for many of the company's previously top-selling drugs, including Norvasc™, Zoloft™, Zithromax™, Diflucan™ and Viagra™. Dr. Mehta currently serves on the board of Targanta, Inc., which is a Radius portfolio company, and was on the boards of a number of U.S. and international biotechnology companies. Dr. Mehta has also served on the board of the Psychopharmacology Advisory Committee of the FDA. Dr. Mehta received his MBBS, M.D. and Ph.D. from the University of Bombay.
		George M. Milne, Jr., Ph.D. became a Radius Venture Partner in 2002. From 1993 to 2000, Dr. Milne served as President of Central Research for Pfizer, Inc. and oversaw both human and veterinary research and development. Following Pfizer's merger with Warner Lambert, he held the position of Executive Vice President of Global Research and Development and also served as President of Strategic and Operations Management. Dr. Milne serves on the board of directors of several Radius portfolio companies, including Athersys, Inc., BioStorage Technologies, Inc., and Rib-X Pharmaceuticals, Inc., where in 2008 he took on the role of Executive Chairman. Dr. Milne previously served on board of two other Radius portfolio companies, Conor Medsystems, Inc. and Phylogix, Inc. Dr. Milne also currently serves on the board of directors of Mettler-Toledo, Inc., Charles River Laboratories, Inc., the Mystic Aquarium-Institute for Exploration and the New York Botanical Garden. Dr. Milne received a B.S. in Chemistry from Yale University and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology.
		Jan Rock became a Venture Partner of Radius Ventures in 2002. Prior to becoming a Venture Partner, Ms. Rock, through her venture capital firm, MedCapital, had a strategic relationship with Radius that included deal sourcing, due diligence, co-investing and a membership interest in the General Partner of Radius II. MedCapital makes investments in early-stage healthcare companies. Previously, Ms. Rock served as Vice President of Women's Health at Johnson & Johnson ("J&J"). At J&J, she was responsible for expanding the company's two billion dollar franchise in women's health products, which resulted in the $290 million acquisition of Biopsys Medical, the $79 million acquisition of Gynecare, Inc., and the creation of a new J&J venture, Women's First Healthcare. Ms. Rock currently serves on the board of directors of U-Systems, Inc., a Radius portfolio company. She has also served as a director or observer to several venture stage companies, including Amicas, Inc. and BEI Medical, Inc. (both Radius portfolio companies) as well as Immunicon, Inc., Protocare, Inc, and Purilens, Inc. Ms. Rock received a B.A. in Economics from Cornell University and an M.B.A. from the Harvard Business School.

Advisory Board

Our Advisory Board serves as a brain trust, offering leadership, industry contacts and resources.

Brian J. Brille is a Managing Director and Global Head of Investment Banking of Banc of America Securities. Mr. Brille was previously a Managing Director and Head of Healthcare Services Investment Banking at Morgan Stanley & Co., Inc.

Vincent S. Conti is the recently retired President and Chief Executive Officer of Maine Medical Center (MMC). Under his leadership, MMC repeatedly earned national recognition for the quality of its clinical services. Previously, Mr. Conti held the position of Senior Vice President-Administration at the Yale-New Haven Hospital. While at MMC, Mr. Conti was elected to the Board of the American Hospital Association (AHA), and the board of Health Insights.

Steven B. Epstein, Esq. is the founder of Epstein Becker & Green, P.C., one of the largest national healthcare law firms in the United States. As a Senior Partner of the firm, he provides health care organizations and providers with strategic legal guidance on a range of issues and legal challenges relating to the American health care system. Mr. Epstein currently sits on the boards of a number of health care companies, including Discovery Health, HealthExtras and Emergency Medical Services Corp.

Scott T. Garrett is President and Chief Executive Officer of Beckman Coulter, Inc., one of the world's largest manufacturers of biomedical tests, instrumentation and supplies. Previously, Mr. Garrett served as Chief Executive Officer of Garrett Capital Advisors, LLC, Kendro Laboratory Products, and Dade Behring (a spinout of Baxter International). His prior experience also includes leadership positions at Baxter International and American Hospital Supply Corporation.

William A. Hawkins is the President and Chief Executive Officer of Medtronic, Inc. Previously, he has held the positions of President and CEO of Novoste Corporation; President of Sherwood Davis & Geck, (a subsidiary of American Home Products); President of Ethicon Endo-Surgery, Inc. (subsidiary of Johnson & Johnson); President and CEO of IVAC, an Eli Lilly subsidiary, and President of Devices for Vascular Intervention of Guidant (following its spin-off from Eli Lilly).

Javier Lopez Madrid is an Executive Director of the Villar Mir Group ("VMG"), one of the largest privately-held industrial holding groups in Spain. Mr. Lopez Madrid is also the founder and Chairman of STH Capital, a venture capital partnership focused on them biotechnology, financial services and telecommunications industries.

David McGibney, MB, Ch.B., FRCP, FFPM is the Chairman of the Development Advisory Board of Athersys, Inc., a Radius portfolio company. David joined Pfizer in Europe in 1982 and was appointed head of European Clinical Development for Pfizer Central Research in 1992. He was later named Vice President of Clinical Research and a member of the Board of Directors of Pfizer Ltd in 1995. Prior to leaving Pfizer in 2001, he was Senior Vice President of Pfizer Global Research and Development and Director of the R & D Laboratories in Sandwich, Kent, UK.

James I. McLaren is a Managing Director of Asante Partners, LLC, an investment banking business which he founded in 1992 at EGS Securities Corp. He is also a Member of EGS Private Healthcare Associates, LLC, a private equity investment fund, and was formerly director of RTP Pharma, Inc., a drug delivery company that was purchased by SkyePharma plc.

Jeffrey W. Moses, M.D. is the Director of the Center for Interventional Vascular Therapy at Columbia University Medical Center and an interventional cardiologist at New York- Presbyterian Hospital and Columbia University Medical Center.

Thomas F. O'Donnell, Jr., M.D. is the former President and CEO of the Tufts New England Medical Center and is currently the Senior Vascular Surgeon at Tufts New England and the Benjamin Andrews Professor of Surgery Emeritus at Tufts University School of Medicine.

Mehmet C. Oz, M.D. is Vice-Chairman of Surgery and Irving Professor of Cardiac Surgery at Columbia University. He is the Director of the Cardiovascular Institute, the Director of Clinical Trials of New Surgical Technology, and is a Director and founder of the Complementary Medicine Program at New York Presbyterian Medical Center.

Stephen G. Pagliuca is a Managing Director of Bain Capital and has been involved in over 30 acquisitions of significant information technology and medical companies including Gartner Group, Burger King Corporation and ProSiebenSat.1 Media AG. Previously, Mr. Pagliuca was a partner at Bain & Company.

W. Norman Scott, M.D. is Director of the Insall, Scott & Kelly Clinic in New York and Clinical Professor of Orthopedic Surgery at Albert Einstein College of Medicine. He was the founding member and President of the Knee Society. Dr. Scott was also the founder of Pro Team Physicians and has served as the Team Physician for the New York Knicks since 1978.

Leon G. Smith, M.D. is Chairman of Medicine and former Chief of Infectious Diseases at St. Michael's Medical Center in Newark, NJ. He is also Chairman of Medicine at the Seton Hall University School of Graduate Medical Education and Professor of Preventative Medicine at New Jersey Medical School.

Mark S. Speers is Managing Director and co-founder of Health Advances, LLC, a strategy consulting firm focused on the evaluation and commercialization of new medical technologies and services. Previously, Mr. Speers served as a Partner at Bain & Company where he consulted for major health and life sciences companies.

Arthur H. Spiegel III is the former President of CSC Healthcare, which he developed into one of the nation's leading healthcare IT providers, delivering management consulting, systems integration, full-service IT outsourcing, and claims processing systems and services to the life sciences, health plan and provider markets. Mr. Spiegel currently serves on the board of directors of EyeTel Imaging, Inc. and BioStorage, Inc., both Radius portfolio companies.

Barry W. Wilson is the recently retired Senior Vice President, International of Medtronic, Inc. He joined Medtronic, Inc. in 1995, as President Europe, Middle East & Africa. Previously, Mr. Wilson held executive-level positions with American Cyanamid Company (President, International of the Lederle Division), Bristol-Myers Squibb (President, Europe) and Pfizer. He currently serves as Honorary Chairman of Eucomed, the pan-European medical technology trade association, and has been a senior advisor to AdvaMed, the U.S. medical device association.

 

Strategic Relationships

We have established several important relationships with outstanding organizations that augment our investment capabilities and enhance our value-added proposition to our portfolio companies.

• Bain Capital and Radius have enjoyed a close and special relationship which was initially established in Radius I. Bain is a special member of the General Partner of Fund I, Fund II, and Fund III. The Bain relationship includes a capital commitment to Fund III by Bain or its affiliates, and provides for Bain to direct deal flow to Radius, taking into account the policies, duties, and obligations of Bain to the funds advised by Bain or its affiliates. Over the last eight years, Bain has proven to be an active source of deal flow for the Radius funds.
• Health Advances is a strategy consulting firm focused on the evaluation and commercialization of new medical technologies and services. Its staff includes professionals with strong technical and clinical credentials. Our relationship with Health Advances expands Radius' knowledge base across the broad health and life sciences sector, and provides our portfolio companies access to Health Advances' expertise and vast industry and professional network.

Limited Partners

Radius has attracted a strong group of investors who can contribute to the success of our portfolio companies. Our investors include CEOs and senior professionals from a broad cross-section of the health and life sciences industry.